Tabbatar da Ingantaccen Taimakawa Forsig

Forsiga ita ce kawai SGLT2 inhibitor tare da ingantaccen inganci da aminci fiye da shekaru 4 na amfani. Tabletaya daga cikin kwamfutar hannu a kowace rana, ba tare da la'akari da cin abinci ba, yana ba da tabbacin raguwar hauhawar jini, hauhawar raguwa mai narkewa a cikin ƙwayar haɓaka, da hauhawar raguwar nauyin jiki. Ba'a nuna magungunan don maganin kiba da hauhawar jini ba. Sakamakon binciken ya kasance ƙarshen gwaji na biyu a gwaji na asibiti.

Wanene aka wajabta maganin?

Dapagliflozin (nau'in ciniki na Forxiga) a cikin aji na kwayoyi - masu hana sodium-glucose-cotransporter nau'in 2 (SGLT-2) ya bayyana a kasuwar magunguna na Rasha da farko. Anyi rajista a cikin maganin monotherapy don kula da ciwon sukari na 2, har ma a hade tare da Metformin a matsayin magani na farawa da kuma ci gaba da cutar. A yau, kwarewar da aka tara tana ba mu damar amfani da maganin don masu ciwon suga "tare da gogewa" a cikin dukkan abubuwan haɗuwa:

• Tare da abubuwan da aka samo daga sulfanilurea (gami da illolin motsa jiki tare da metformin);
• Tare da gliptins;
• Tare da thiazolidinediones;
• Tare da hanawar DPP-4 (yiwu a hade tare da metformin da analogues);
• Tare da insulin (da ƙari wakilai na hypoglycemic na bakin jini).

Ga wanda aka hana mai hana shi

Kada a rubanya Forsig ga masu ciwon sukari tare da nau'in cuta na 1. Tare da rashin yarda da mutum ga abubuwan da aka kirkiran, ana maye gurbinsu da analogues. Hakanan ba a nuna Dapagliflozin:

• Game da matsalolin koda na koda, da idan an rage yawan tacewa zuwa 60 ml / min / 1.73 m2;
• Ketoacidosis mai ciwon sukari;
• Rashin haɗarin Lactose;
• Rashin lalacewa da haɓaka haɓakar glucose-galactose;
• Haihuwa da lactation;
• A lokacin ƙuruciya da samari;
• A lokacin shan wasu nau'ikan magungunan diuretic;
• Cututtuka na ciki;
• Tare da anemia;
• Idan jiki ya bushe;
• A balagagge (daga shekara 75), idan an wajabta maganin a karon farko.

Amfani da Forsigi yana buƙatar taka tsantsan, idan an haɓaka hematocrit, akwai cututtukan cututtukan ƙwayar cuta, rashin lafiyar zuciya a cikin yanayin rashin ƙarfi.

Amfanin Dapagliflozin

Ana samun sakamako na warkewa ta hanyar hana sodium glucose cotransporter, glucouria na pharmacological, wanda ke tattare da asarar nauyi da raguwa a cikin karfin jini. Wannan kayan da ke cikin murhunniyar da ba na insulin-ciki ba zai sami fa'idodi da yawa:

• Ingantaccen aiki baya dogaro da ƙwaƙwalwar nama zuwa insulin;
• Hanyar aiwatarwa ba ta ɗaukar nauyin β-sel;
• Ingantaccen haɓaka ƙarfin β-cell;
• Rage raguwar insulin;
• Riskarancin haɗarin hauhawar jini wanda yake daidai da placebo.

An aiwatar da tsarin insulin-mai zaman kansa na aiki a cikin dukkan abubuwan da za'a iya haɗuwa, a kowane matakai na kula da haƙuri - daga halarta na farko zuwa nau'ikan ciwon sukari na ci gaba, lokacin haɗuwa da insulin ya zama dole. Itsarfin ƙarfinsa ba a yi nazari ba yayin da aka haɗa shi da agonists na masu karɓa na GLP-1.

Tsawon lokacin cutar ba ta shafi ikon dapagliflozin. Ba kamar sauran analogues masu tasiri kawai a cikin shekaru 10 na farkon ci gaban ciwon sukari ba, Forsigu zai iya yin nasarar amfani da masu ciwon sukari "tare da gwaninta."

Bayan ƙarshen hanya na ɗaukar mai hanawa, sakamako na warkewa yana isa tsawon lokaci. Yawancin zai dogara da aikin kodan.

Magungunan yana taimaka wa marasa lafiya masu hauhawar jini kula da karfin hawan jini, suna samar da sakamako mai laushi. Wannan bi da bi yana taimakawa rage haɗarin ci gaban yanayin cututtukan zuciya.

Forsyga da sauri yana daidaita ƙwayar cutar glycemia, amma maida hankali ga ƙwayoyin cholesterol (duka duka biyu da LDL).

M cutarwa ga dapagliflozin

Shekaru hudu ba tsaftataccen lokacin aiki bane na asibiti.

Idan aka kwatanta da shirye-shiryen metformin da aka yi nasarar amfani da su tsawon shekarun da suka gabata, ba a yi nazarin tasirin Forsigi na dogon lokaci ba a duk fannoni.

Ba za a iya magana game da magani na kai tare da Forsiga ba, amma koda likita ya tsara maganin, dole ne mutum ya saurari yanayinsa, rubuta duk canje-canje don gargadi likita a kan lokaci. Waɗannan sharuɗɗan sun haɗa da:

• Polyuria - karuwar fitowar fitsari;
• Polydipsia - yawan jin ƙishirwa;
• Manyan ƙwayar cuta - haɓakar yunwa;
• Gajiya da haushi;
• Rage nauyi mara nauyi;
• Saurin warkar da raunuka;
• Kwayar cikin mahaifa tare da itching da fitsarin makwancin gwaiwa;
• Glucosuria (bayyanar glucose a cikin gwajin fitsari);
• Cutar mahaifa;
• Cramps na dare a cikin kafafu (saboda karancin ruwa);
• Oarancin neoplasia (isasshen bayani);
• Oncology na mafitsara da prostate (bayanan da ba a tabbatar ba);
• Take hakkin rudani na hanjin motsi;
• Wuce kima;
• Levelsara matakan urea da creatinine a cikin jini;
• Ketaocidosis (nau'in ciwon sukari);
• Dyslipidemia;
• Ciwon baya.

Yana da mahimmanci a tuna cewa dapagliflozin yana tsokani aikin haɓakar haɓaka, na tsawon lokaci, aikin su yana raguwa, kamar yadda ƙirar fillo ɗin glomerular. Ga masu fama da cutar sankara, kodan sune mafi raunin garkuwar jiki, idan har akwai matsaloli a wannan bangaren, to ya kamata a watsar da duk wata hanyar Forsigi analogues. Wani nau'in ci gaba na cututtukan cututtukan cututtukan ƙwayar cuta ya ƙunshi tsabtace mutum mai ƙwaƙwalwa ta hanyar hemodialysis.

Glucosuria (babban taro na sukari a cikin gwajin fitsari) yana da mummunar tasiri a cikin ƙwayar urinary. Mai hanawa yana kara yawan fitsari “mai dadi”, kuma da shi akwai yiwuwar kamuwa da cuta tare da jan ciki, ƙaiƙayi, da rashin jin daɗi. Mafi sau da yawa, irin waɗannan alamun, saboda dalilai na bayyane, ana lura dasu tsakanin mata.

Yana da haɗari don amfani da inhibitor a cikin nau'in 1 na ciwon sukari, saboda ƙwanjamain da jikin ke karɓar abinci shi ma kodan ya keɓe shi. Hadarin hypoglycemia, wanda da sauri ya canza zuwa magabata da coma, yana ƙaruwa.

Babu wani cikakken hoto game da ketoacidosis masu ciwon sukari. An bayar da rahoton lokuta daban-daban waɗanda za a iya danganta su da wasu abubuwan haɗin gwiwa na cututtukan metabolism.

Kulawa da hanzari na hanzari na kawar da jiki da sauri kuma yana iya zama haɗari.

Hanyar tasiri Forsigi

Babban aikin dapagliflozin shine rage ƙwanƙwaran ƙofa don juyawa daga narkewar sukari a cikin tubules na koda. Kodan shine babban kayan jikin mutum wanda yake tsabtace jini kuma yana cire abubuwa da yawa daga fitsari. Muna da jikin mu yadda muke tantance ingancin jini wanda ya dace da rayuwarsa. Matsayi na "gurbatawar" kuma ƙididdigar ƙididdigar ta ƙididdigar ta.

Matsawa ta hanyar yanar gizo na tasoshin jini, yana tace jini. Idan ƙwayoyin ba su dace da juzu'in abin da aka tace ba, jikin zai cire su. Lokacin tacewa, ana yin nau'in fitsari guda biyu. Primary shine, a zahiri, jini, kawai ba tare da furotin ba. Bayan farkon tsabtatawa mai tsabta, ana gudanar da aikinta. Fitsari na farko ya fi na sakandare komai girma, wanda yake tattarawa kowace rana tare da metabolites kuma kodan ke cire shi.

A cikin nau'in ciwon sukari na 2, gwajin fitsari ya haɗa da glucose da jikin ketone, wanda ke nuna hyperglycemia, wanda zai iya ɗaukar dogon lokaci. Irin waɗannan abubuwan wuce haddi sun wuce iyakar ƙima ga kodan (10-12 mmol / l), saboda haka, lokacin haɓaka fitsari na farko, ana amfani dashi wani ɓangare. Amma wannan yana yiwuwa ne kawai da rashin daidaituwa.

Masana ilimin kimiyya sunyi ƙoƙarin yin amfani da waɗannan ƙarfin kodan don saita su don magance cutar glycemia da sauran dabi'un sukari, kuma ba kawai tare da hyperglycemia ba. Don yin wannan, ya zama dole don rushe tsarin jan girkin, wanda ya sa yawancin glucose din suka kasance cikin fitsari na biyu kuma an cire shi lafiya ta jiki.

Nazarin ya nuna cewa sodium cotransporters wanda aka keɓance a cikin nephron shine tushen sabon insulin mai cin gashin kansa don daidaitawar glucose. A al'ada, 180 g na glucose an shafa shi gaba daya a cikin dukkanin glomeruli yau da kullun kuma kusan dukkanin shi an sake shiga cikin jini a cikin tubule mai kusanci tare da sauran mahallin da ke buƙatar matakan tafiyar matakai. SGLT-2, wanda yake cikin s1 na proximal tubule, yana da alhakin kusan 90% na reabsorption na glucose a cikin kodan. A cikin yanayin hyperglycemia, a cikin marasa lafiya da ke dauke da ciwon sukari na 2, SGLT-2 ya ci gaba da sake sarrafa glucose, babban tushen adadin kuzari, zuwa cikin jini.

Haramcin sodium glucose-cotransporter type 2 SGLT-2 shine sabon hanyar da ba ta da insulin-magani a cikin lura da nau'in ciwon sukari na 2, yana ba da gudummawa ga warware matsalolin da yawa na sarrafa glycemic. Fati ta farko a cikin tsari ana yin ta ne ta hanyar jigilar kayan masarufi, musamman SGLT-2, wanda ke kama glucose don yalwata sha a cikin kodan. SGLT-2 inhibitors suna da tasiri sosai don fitarwar glucose a cikin adadin 80 g / day. A lokaci guda, adadin makamashi yana raguwa: mai ciwon sukari yana asarar har zuwa 300 Kcal a kowace rana.

Forsyga wakilin aji ne na SGLT-2 inhibitors. Hanyar aikinta shine toshewa da kuma ɗaukar glucose a cikin sashi na S1 na tubule na proximal. Wannan yana tabbatar da fitar da glucose din a cikin fitsari. A dabi'ance, bayan shan Forsigi, masu ciwon sukari sukan ziyarci bayan gida: kullun osmotic diuresis yana ƙaruwa da 350 ml.

Irin wannan aikin insulin-mai zaman kansa yana da matukar mahimmanci, tunda β-sel na kankantar lokaci tare da lokaci, kuma jinkirin insulin yana taka muhimmiyar rawa a ci gaban nau'in ciwon sukari na 2. Tunda aikin inhibitor bai shafi yawan insulin ba, yana da kyau ayi amfani dashi da nau'in ciwon sukari na 2 a hade tare da metformin da analogues ko shirye-shiryen insulin.

Magungunan Forsiga - kwararru na kwararru

Anyi nazari sosai game da gwajin a asibiti, gami da kashi na uku na gwaji, wanda sama da dubu 7 suka ba da gudummawa. Tsarin farko na binciken shine monotherapy (ciki har da tasiri na ƙananan allurai), na biyu shine haɗuwa tare da sauran wakilai na hypoglycemic (metformin, DPP-4 inhibitors, insulin), zaɓi na uku shine tare da ƙayyadaddun sulfonylurea ko metformin. An yi nazarin tasiri na allurai guda biyu na Forsig - 10 MG da 5 MG a haɗe tare da metformin na tasirin shirye-shiryen, musamman, tasirin magungunan ga marasa lafiya masu hauhawar jini.

Forsiga ya sami mafi girman bita daga masana. Sakamakon binciken ya tabbatar da cewa yana da tasiri mai mahimmanci a cikin matakin glycated haemoglobin tare da babban bambanci daga rukunin placebo, tare da haɓakar HbA1c na kusan ɗaya (matsakaicin dabi'u lokacin da aka haɗu da insulin da thiazolidinediones) a ƙimar farko na babu sama da 8%. Lokacin da aka bincika rukuni na marasa lafiya wanda a farkon matakin cutar haemoglobin ya zama mafi girma daga 9%, bayan makonni 24 canje-canje na HbA1c a cikin su ya juya ya zama mafi girma - 2% (tare da monotherapy) da 1.5% (a cikin bambance-bambancen daban-daban na maganin haɗin gwiwa). Duk bambance-bambance sun kasance abin dogaro idan aka kwatanta da placebo.

Forsiga yana tasiri sosai a matakin mai yawan cutar glycemia. Matsakaicin martani ana bayarwa ta hanyar haɗuwa dapagliflozin + metformin, inda ƙarfin ayyukan alamun sukari mai azumi ya wuce 3 mmol / l. Valuididdigar sakamakon tasirin cutar bayan aikin ƙwayar cuta ta faru bayan makonni 24 na maganin. A duk haɗuwa, an sami babban bambanci idan aka kwatanta da placebo: monotherapy - debe 3.05 mmol / L, ƙari na sulfonylureas zuwa shirye-shiryen - ramin 1.93 mmol / L, haɗuwa tare da thiazolidinediones - debe 3.75 mmol / L.

Assessmentididdigar tasirin maganin yana haifar da asarar nauyi shima abin lura ne. Dukkanin matakan karatun sunyi rubuce-rubucen asarar nauyi mai nauyi: tare da monotherapy matsakaita na 3 kilogiram, lokacin da aka haɗa shi da kwayoyi waɗanda ke inganta yawan nauyin (insulin, sulfonylureas) - 1.6-2.26 mmol / L. Forsyga a cikin hadaddun farji na iya kawar da illa mara kyau na magunguna waɗanda ke ba da gudummawar samun nauyi. Thirdaya bisa uku na masu ciwon sukari masu nauyin kilogram 92 ko fiye da suka karɓi Forsigu tare da Metformin sun sami sakamako mai mahimmanci a cikin makonni 24: ƙara girman 4.8 kg (5% ko ƙari). Hakanan anyi amfani da alamar alamar maye (keɓewa ta ciki) a cikin kimantawar tasiri. Tsawon watanni shida, an yi rikodin raguwa a cikin kugu (a matsakaici - da 1.5 cm) kuma wannan sakamako ya ci gaba da ƙaruwa bayan makonni 102 na jiyya (aƙalla 2 cm).

Nazarin na musamman (mai amfani da hasken rana mai ɗaukar haske) ya kimanta fasali na asarar nauyi: 70% a cikin makonni 102 ya kasance saboda asarar kitse na jiki - visceral (a kan gabobin ciki) da subcutaneous. Nazarin tare da kwatancen magani sun nuna ba kawai inganci mai dacewa ba, riƙe tsawon lokaci na tasirin Forsigi da Metformin na shekaru 4 na lura, amma kuma yana da nauyi asara idan aka kwatanta shi da ƙungiyar shan Metformin a hade tare da abubuwan da aka samo na sulfonylurea, inda aka lura da samun nauyin 4.5 kilogram.

Lokacin nazarin alamomin hawan jini, ƙarfin kumburin jini na systolic shine 4,4 mm RT. Art., Diastolic - 2.1 mm RT. Art. A cikin masu fama da cutar hawan jini wanda ke da adadin kwastomomi har zuwa mm mm 150. manyan masu karɓar magungunan antihypertensive, ƙarfin kuzari ya fi 10 mm RT. Art., Sama da 150 mm RT. Art. - fiye da 12 mm RT. Art.

Shawarwarin don amfani

Ana amfani da wakili na baki a kowane lokaci, komai abinci. Allunan da aka yi awo 5 da 10 MG a cikin kwali na 28, 30, 56 da 90. Daidaitaccen shawarar don Forsigi da aka wajabta a cikin umarnin don amfani - 10 MG / rana. Oraya daga cikin allunan guda ɗaya ko biyu, dangane da sashi, sun sha sau ɗaya, tare da ruwa.

Idan ayyukan hanta ba su da kyau, likita zai rage al'ada a cikin daya da rabi zuwa sau biyu (tare da farawar farko 5 MG / rana.).

Mafi na kowa shine haɗuwa da Forsigi tare da Metformin ko analogues. A cikin irin wannan haɗin, 10 wajabta na inhibitor da har zuwa 500 MG na metformin ana wajabta su.

Don rigakafin cututtukan hypoglycemia, ya kamata a rubuta Forsig a hankali a kan tushen ilimin insulin kuma a hade tare da magunguna na ƙungiyar sulfonylurea.

Don iyakar ƙarfin, yana da kyau a sha maganin a lokaci ɗaya na rana.

Ba tare da gyara salon rayuwa ba, kimar mai hana mai hana ruwa gudu ba shi da ma'ana.

Daidaita magani tare da glyphlozines (daga 10 mg) zai rage ƙimar HbA1c.

Idan a cikin hadaddun jiyya akwai kuma insulin, to glycated haemoglobin an rage sosai. A cikin tsarin hadaddun, tare da nadin Forsigi, ana sake nazarin yawan sashin insulin. Cikakken ƙin yarda da allurar hormonal mai yiwuwa ne, amma duk waɗannan maganganun suna cikin kwarewa ne na kamuwa da maganin endocrinologist.

Shawara ta musamman

Ya kamata a kula da marasa lafiya da rashin isasshen ƙwayar ƙwayar cuta tare da ƙara hankali: yi amfani da Forsigu a cikin hadadden daidaita, saka idanu a kai a kai yanayin yanayin ƙodan, daidaita sashi kamar yadda ya cancanta. Tare da tsawaitawa (daga shekaru 4), zaka iya maye gurbin dapagliflozin lokaci-lokaci tare da madadin magunguna - Novonorm, Diagnlinid.

An wajabta likitan zuciya ga masu ciwon sukari masu fama da cututtukan zuciya da na jijiyoyin jiki a layi daya tare da magunguna masu rage sukari, tunda dapagliflozin yana da ikon ƙirƙirar ƙarin nauyi akan tasoshin.

Yawan yawan bayyanar cututtuka

Gabaɗaya, maganin ba shi da lahani; a cikin gwaje-gwajen, masu sa kai ba tare da masu ciwon sukari ba sun yarda da yawan lokaci-lokaci na adadin sau 50. An gano sukari a cikin fitsari bayan irin wannan kashi na tsawon kwanaki 5, amma ba a yin rubutu na hypotension, hypoglycemia, ko dehydration mai tsanani.

Tare da yin amfani da makonni biyu na amfani da kashi 10 sau na yau da kullun, duka masu ciwon sukari da mahalarta ba tare da irin waɗannan matsalolin ba sun haɓaka ƙwanƙwasa yanayin zafi kaɗan fiye da tare da placebo.

Idan mai haɗari ko yawan ganganci, yawan tsabtace ciki da aikin kulawa ana yin su. Ba a bincika Fitar ta Forsigi ta hanyar hemodialysis.

Shin yana yiwuwa a rasa nauyi tare da Forsiga

An tabbatar da sakamakon rasa nauyi an tabbatar da shi a gwaji, amma yana da haɗari a yi amfani da maganin na musamman don gyaran nauyi, saboda haka ana sakin magunguna kawai ta hanyar sayan magani. Dapagliflozin ya sa baki cikin yanayin aiki na koda da ƙodan. Wannan rashin daidaituwa yana shafar aikin dukkan gabobin da tsarin sa.

Jikin yana bushewa. Hanyar aiwatar da maganin yana kama da tasirin abinci mai ƙoshin gishiri, wanda ba ku damar rasa 5 kilogiram a cikin makonni na farko. Gishiri yana riƙe da ruwa, idan kun rage amfani dashi, jiki zai cire ruwan da yawa.

An rage yawan adadin kuzari. Lokacin da glucose bai cika ba, amma ana amfani dashi, wannan yana rage adadin kuzarin mai shigowa: 300-350 kcal ana cinye kowace rana.

Idan baku cika jiki da carbohydrates, nauyi zai tafi sosai.

Sharpin yarda da amfani da inhibitor baya bada garantin zaman lafiyar sakamakon da aka samu, saboda haka ba a bada shawara ga mutane masu lafiya suyi amfani da maganin ƙwaƙwalwar ƙwayar cuta na musamman don daidaita nauyin jikin.

Sakamakon Cutar Magunguna

Mai hanawa yana inganta yuwuwar diuretic, yana kara haɗarin rashin ruwa da hauhawar jini.

Dapagliflozin cikin nutsuwa tare da metformin, pioglitazone, sitagliptin, glimepiride, valsartan, voglibose, bumetanide. Haɗuwa tare da rifampicin, phenytoin, carbamazepine, phenobarbital ba su da tasiri sosai a kan magunguna na magunguna, amma wannan bai shafi fitowar glucose ba. Babu daidaitawar sashi na dole tare da hadewar Forsigi da mefenamic acid.

Forsyga, bi da bi, ba ya rage ayyukan metformin, pioglitazone, sitagliptin, glimepiride, bumetanide, valsartan, digoxin. Sakamakon ikon simvastatin ba mahimmanci bane.

Sakamakon magunguna na Forsigi shan taba, barasa, abinci daban-daban, magunguna na ganye ba a yi nazari ba.

Sharuɗɗan siye da ajiya

Idan kayi la'akari da cewa an tsara magungunan azaman zaɓi, farashinsa ba zai zama mai araha ba ga kowa: don Forsig farashin yana daga 2400 - 2700 rubles. don allunan 30 waɗanda ke awo 10 MG. Kuna iya siyan akwatin tare da blisters biyu ko huɗu na aluminium a cikin cibiyar sadarwar kantin magani tare da takardar sayan magani. Wani yanayi na musamman na marufi kayan kariya ne mai kariya mai ma'ana tare da tsari tare da layin hawaye a cikin hanyar farin raga.

Magungunan ba ya buƙatar yanayi na musamman don ajiya. Ya kamata a sanya kayan agajin farko a wuri mara amfani ga hankalin yara, a ƙarƙashin yanayin zafin jiki har zuwa 30 ° C. A ƙarshen ranar karewa (bisa ga umarnin, wannan shekaru 3), ana zubar da maganin.

Forsiga - analogues

Kawai uku ana musayar analogous SGLT-2 magunguna sun ci gaba:

• Jardins (sunan alama) ko empagliflozin;
• Invocana (zaɓi na kasuwanci) ko canagliflozin;
• Forsiga, a cikin tsarin ƙasa - dapagliflozin.

The kama a cikin sunan nuna cewa sun hada da guda aiki bangaren. Kudin magungunan analog daga 2500 zuwa 5000 rubles. Ga magungunan Forsig, babu tsararrun analogues duk da haka, idan sun bunkasa ƙwayoyin cuta a gaba, to, mafi kusantar su, bisa tushen ɓangarorin magungunan.

Nazarin haƙuri

Takaitawa

Tare da duk hanyoyi da magunguna iri daban-daban na maganin cututtukan type 2, akwai wasu maganganu marasa warwarewa.

1. Cutar rashin lafiya na karshen cutar (yana rage tsammanin rayuwa ta shekaru 5-6).
2. Hanyar ci gaba na ciwon sukari, ba tare da la'akari da magani ba.
3. Fiye da 50% ba su cimma burin warkewa kuma kar ku kula da sarrafawar glycemic.
4. Sakamakon sakamako: hauhawar jini da riba mai nauyi - farashin ingancin sarrafa glycemic.
5. Babban haɗarin haɗarin cututtukan zuciya (CVS).

Yawancin masu ciwon sukari suna da cututtukan haɗin gwiwa waɗanda ke kara haɗarin CVD - kiba, hauhawar jini, da dyslipidemia. Rage kilo ɗaya na nauyi ko canza murfin gero ta 1 cm yana rage haɗarin haɓakar cututtukan zuciya na zuciya da 13%.

An tabbatar da jiran rayuwa a duk duniya ta hanyar lafiyar zuciya. Dabarun inganta ingantaccen hadarin SS:

• Gyara rayuwa;
• Gyara aikin metabolism;
• Rage saukar karfin jini;
• Normalization na carbohydrate metabolism.

Daga wannan ra'ayi, ingantaccen magani yakamata ya ba da izinin sarrafa glycemic 100%, ƙananan haɗarin hypoglycemia, ingantacciyar tasiri akan nauyin jikin mutum da sauran abubuwan haɗari (musamman, hawan jini, haɗarin CVD). A wannan batun, Forsig ya cika dukkan bukatun zamani: raguwa mai yawa a cikin gemocated haemoglobin (daga 1.3%), ƙananan haɗarin hauhawar jini, asarar nauyi (a rage girman 5.1 kg / shekara tare da dagewa na shekaru 4), da raguwar hauhawar jini (daga 5 mmHg) A sakamakon da aka haɗa sakamakon nazarin guda biyu sun nuna cewa bayanan martaba na inganci da amincin ƙwayar Forsig a cikin lura da masu ciwon sukari tare da cututtukan concomitant daban-daban suna da kyau. Wannan shine mafi yawan magungunan da aka tsara (290 dubu marasa lafiya a cikin shekaru 2).